Acute Lymphoblastic Leukaemia (ALL) – Updates from the European Haematology Association Conference

In June, our team attended the European Haematology Association (EHA) conference. Here they share the latest updates about Acute Lymphoblastic Leukaemia (ALL).

Our campaigns and advocacy team attended the European Haematology Association conference in June to hear the latest news from research, clinical trials and clinical practice. Here are the latest updates from the conference.

Highlights in ALL included:

  • Genetic changes in ALL

Identifying the genetic changes that have happened in ALL cells is becoming increasingly important as new treatments are being developed. It allows therapies to be more targeted to the underlying changes that are driving the disease.

  • Immunotherapies

Immunotherapies use the patients own immune response to treat ALL. There are a number of emerging immunotherapies, currently in clinical trials and the research was presented at the meeting.

  • CAR-T therapy

A very hot topic in the treatment of ALL at the moment. CAR-T therapy is the first gene therapy to be approved for use in America and it has now been approved in Europe. Much research was presented at the meeting, including clinical trial data and looking for new cancer cell markers that can be targeted with edited immune cells.

Learn more from the clinicians in the video below:

View more videos from the conference by visiting our YouTube page here.


#LeukaemiaLevy petition

If you agree that leukaemia patients and their families deserve more financial support, sign our petition and help us make cancer patients’ voices heard.

Read More